LAUSR

The first monoclonal antibody approved for veterinary use in the european Union, Cytopoint, was launched this week. A single injection of Cytopoint treats the clinical signs of atopic dermatitis in dogs, including itch and inflammation, for up to one month. The monoclonal antibody (MAb) treatment works by mimicking the activity of natural antibodies to selectively bind to and neutralise interleukin 31 (IL-31), a key protein involved in cell communication which triggers itching associated with atopic dermatitis in dogs. Because it neutralises IL-31, it has been demonstrated not to interfere with the immune response, meaning that it does not induce unintended immunosuppression or enhancement. Manufacturer Zoetis says treatment provides long-lasting relief from itching and inflammation within eight hours, allowing damaged skin to heal, in this way it improves the long-term quality of life for atopic dogs and their owners. In clinical studies submitted to the european Medicines Agency, the efficacy of cytopoint was evaluated and showed that treatment reduced itching and the severity of skin disease. As well as improved efficacy, no adverse effects were reported and it was not found to interact with other drugs.